PP - PRIMARY CUTANEOUS CD8+ T-CELL LYMPHOMA: A CASE REPORT WITH UNUSUAL FACIAL INVOLVEMENT AND AN AGGRESSIVE CLINICAL COURSE

2017 ◽  
Vol 123 (2) ◽  
pp. e56
Author(s):  
DAPHINE CAXIAS TRAVASSOS ◽  
DARCY FERNANDES ◽  
ELAINE MARIA SGAVIOLI MASSUCATO ◽  
CLAUDIA MARIA NAVARRO ◽  
MIRIAN APARECIDA ONOFRE ◽  
...  
Keyword(s):  
Case Report ◽  
T Cell ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
Cd8 T Cell ◽  
T Cell Lymphoma ◽  
Aggressive Clinical Course

Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis.

1987 ◽  
Vol 5 (2) ◽  
pp. 208-215 ◽  
Author(s):  
E Dmitrovsky ◽  
M J Matthews ◽  
P A Bunn ◽  
G P Schechter ◽  
R W Makuch ◽  
...  
Keyword(s):  
T Cell ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
Large Cell ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Blood Smears ◽  
Large Cell Lymphoma ◽  
Aggressive Clinical Course ◽  
Peripheral Blood Smears

The clinical course of cutaneous T cell lymphoma (mycosis fungoides and Sezary syndrome) is generally indolent, but in occasional patients becomes fulminant. We found that biopsies from patients with accelerating disease can reveal cytologic transformation from previously observed small, convoluted lymphocytes to large cells that are similar to cells seen in large-cell lymphoma. The cerebriform nuclei characteristic of malignant T cells can only rarely be identified. Of 150 cutaneous T cell lymphoma patients we treated from 1976 to 1984, cytologic transformation was identified in 12 after review of peripheral blood smears and biopsies from skin, lymph nodes, and visceral sites. Patients who developed cytologic transformation were initially characterized by advanced stage (11 of 12), with lymph node effacement (seven of 11) and erythroderma (five of 12). The tumor cell DNA content after transformation was aneuploid (four of four), and the ability to form rosettes with sheep erythrocytes was retained in transformed cells (three of three). The median time from diagnosis of cutaneous T cell lymphoma to cytologic transformation was 21.5 months (range, 4 to 64), and the median survival from transformation was only 2 months (range, 0 to 19+). We conclude that cytologic transformation in cutaneous T cell lymphoma represents a distinct clinicopathologic entity, characterized by an aggressive clinical course.

Hodgkin-like peripheral T-cell lymphoma (PTCL) with preserved Hodgkin-like lesions at autopsy: A case report with an interesting clinical course

2015 ◽  
Vol 211 (1) ◽  
pp. 83-87
Author(s):  
Daisuke Mori ◽  
Eijo Matsuishi ◽  
Michiaki Akashi ◽  
Masami Shibaki ◽  
Takayuki Hirano ◽  
...  
Keyword(s):  
Case Report ◽  
T Cell ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Peripheral T Cell Lymphoma

Primary cutaneous CD4+ small/medium T-cell lymphoma with aggressive clinical course

2014 ◽  
Vol 55 (4) ◽  
pp. 304-306 ◽  
Author(s):  
Masahito Yasuda ◽  
Naoya Igarashi ◽  
Yayoi Nagai ◽  
Atsushi Tamura ◽  
Osamu Ishikawa
Keyword(s):  
T Cell ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Aggressive Clinical Course

scholarly journals THERAPY OF THE RESISTANT FORMS OF SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA

2019 ◽  
Vol 64 (3) ◽  
pp. 353-361
Author(s):  
L. G. Gorenkova ◽  
S. K. Kravchenko ◽  
M. A. Silaev ◽  
N. V. Ryzhikova
Keyword(s):  
T Cell ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
Case Reports ◽  
Clinical Manifestations ◽  
Lymphoproliferative Disorders ◽  
T Cell Lymphoma ◽  
Aggressive Clinical Course ◽  
Rare Group

Introduction. Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) belongs to a rare group of skin lymphoproliferative disorders, which is characterised by panniculitis-like clinical manifestations, the α/β cytotoxic immunophenotype of tumour cells, as well as a multidirectional course from indolent to aggressive forms.Aim. To examine patients with SPTCL having an aggressive clinical course and characterised by refractoriness to several lines of chemotherapy.Results. We present two case reports of patients with a generalised lesions and unfavourable prognostic factors, who achieved complete long-term remission of the disease as a result of gemcitabine chemotherapy.Conclusion. Despite the fact that both observed SPTCL patients demonstrated refractoriness to at least three types of treatment, the use of gemcitabine allowed long-term complete remissions of the disease to be achieved. 

PRIMARY CUTANEOUS CD8+ T-CELL LYMPHOMA: CASE REPORT SHOWING FACIAL EDEMA WITH MARKED SWELLING OF EYELID AND LIP

2017 ◽  
Vol 124 (2) ◽  
pp. e50
Author(s):  
DAPHINE CAXIAS TRAVASSOS ◽  
ELAINE MARIA SGAVIOLI MASSUCATO ◽  
CLÁUDIA MARIA NAVARRO ◽  
ALFREDO RIBEIRO DA SILVA ◽  
ANDREIA BUFALINO ◽  
...  
Keyword(s):  
Case Report ◽  
T Cell ◽  
Cell Lymphoma ◽  
Cd8 T Cell ◽  
T Cell Lymphoma ◽  
Facial Edema

Primary cutaneous acral CD8+ T‐cell lymphoma of the ear: A case report

2019 ◽  
Vol 46 (10) ◽  
pp. 790-793 ◽  
Author(s):  
Emma Ormerod ◽  
Timothy Murigu ◽  
Joya Pawade ◽  
Matthew Beasley ◽  
Giles Dunnill
Keyword(s):  
Case Report ◽  
T Cell ◽  
Cell Lymphoma ◽  
Cd8 T Cell ◽  
T Cell Lymphoma

scholarly journals NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021

2020 ◽  
Vol 18 (11) ◽  
pp. 1460-1467
Author(s):  
Steven M. Horwitz ◽  
Stephen Ansell ◽  
Weiyun Z. Ai ◽  
Jeffrey Barnes ◽  
Stefan K. Barta ◽  
...  
Keyword(s):  
T Cell ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
Bone Marrow Involvement ◽  
T Cell Lymphoma ◽  
Nccn Guidelines ◽  
T Cell Lymphomas ◽  
Hepatosplenic T Cell Lymphoma ◽  
Aggressive Clinical Course ◽  
Worse Prognosis

Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.

Sign in / Sign up

Export Citation Format

Share Document